Nuria Ribelles

Malaga, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Journal: Breast (Edinburgh, Scotland)
Published: February 13, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology
Published: January 29, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology
Published: January 29, 2026

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: October 05, 2025

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Journal: Frontiers in oncology
Published: June 16, 2025

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Journal: Breast cancer research : BCR
Published: December 17, 2024

Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.

Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.

Journal: Breast cancer research and treatment
Published: June 26, 2024

Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.

Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.

Journal: JCO global oncology
Published: March 21, 2024

Named entity recognition for de-identifying Spanish electronic health records.

Named entity recognition for de-identifying Spanish electronic health records.

Journal: Computers in biology and medicine
Published: January 03, 2024

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

Journal: ESMO real world data and digital oncology
Published: November 28, 2023

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Journal: Lancet (London, England)
Published: September 29, 2023

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 06, 2023
Showing 1-12 of 53

Last Updated: 09/26/2026